Quantum BioPharma Ltd.
QNTM
$3.89
-$0.16-3.95%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 36.64% | 17.61% | 21.78% | 71.89% | -18.09% |
| Depreciation & Amortization | -1.77% | 14.72% | 20.28% | 3.36% | 7.99% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -12.69% | -61.97% | 11.89% | 40.41% | 50.50% |
| Operating Income | 12.69% | 61.97% | -11.89% | -40.41% | -50.50% |
| Income Before Tax | -57.37% | 32.13% | -18.24% | -191.31% | -317.90% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -57.37% | 32.13% | -18.24% | -191.31% | -317.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 18.44% | 604.79% | -403.61% | 113.34% | -13.24% |
| Net Income | -58.11% | 43.54% | -38.98% | -197.35% | -350.60% |
| EBIT | 12.69% | 61.97% | -11.89% | -40.41% | -50.50% |
| EBITDA | 13.12% | 63.38% | -11.64% | -41.94% | -52.90% |
| EPS Basic | 12.84% | 70.80% | 66.44% | 36.89% | -11.07% |
| Normalized Basic EPS | 16.18% | 55.38% | 62.29% | 36.76% | -20.44% |
| EPS Diluted | 12.84% | 70.80% | 66.44% | 36.89% | -11.07% |
| Normalized Diluted EPS | 16.18% | 55.38% | 62.29% | 36.76% | -20.44% |
| Average Basic Shares Outstanding | 81.39% | 93.35% | 314.16% | 371.15% | 305.74% |
| Average Diluted Shares Outstanding | 81.39% | 93.35% | 314.16% | 371.15% | 305.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |